Axonyx Inc. is a biopharmaceutical company engaged in the business of acquiring and developing novel post-discovery central nervous system drug candidates primarily in memory and cognition. The Company acquires patent rights to central nervous system pharmaceutical compounds that may have potential market impact, and works to advance the compounds via pre-clinical and clinical development towards regulatory approval. Axonyx has worldwide exclusive patent rights to three main classes of therapeutic compounds designed for the treatment of Alzheimer's disease (AD), Mild Cognitive Impairment and related diseases. It has also acquired patent rights to a class of potential therapeutic compounds designed for the treatment of prion-related diseases. Axonyx licensed these patent rights from New York University and, via a sublicense, from the National Institutes of Health/National Institute on Aging. The Company has co-inventorship rights to Posiphen, which was developed for the treatment of AD.
The CEO said on 9/30/03 that Phensarine "could be fast-tracked."
biz.yahoo.com
Another SI thread, "AXYX - Miscellaneous," is not intented as a discussion thread, but as "a filing cabinet for abstracts and
misc. writings related to AXYX's work
in AD."
Subject 53918
The stock hit the low $20's in 2000, was below $1 as late as April '03, and pushed over $5 twice in Sept and Oct '03. |
